SCHEMBL14733462

SCHEMBL14733462

N#Cc1nc2ccc3ncnc(Nc4cccc(Cl)c4)c3c2s1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 9/20 0.64
DYRK1B Q9Y463 7/20 0.64
EGFR P00533 7/20 0.53
FADS1 O60427 2/20 0.53
ERBB2 P04626 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
PRNP P04156 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.50
KMT2A Q03164 1/20 0.50
LCK P06239 1/20 0.49
MKNK1 Q9BUB5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14733418 0.88 DYRK1A (0.70) DYRK1ADYRK1BEGFR
SCHEMBL14733490 0.86 DYRK1A (0.61) DYRK1ADYRK1B
SCHEMBL16038266 0.86 DYRK1A (0.60) DYRK1ADYRK1BEGFRERBB2MAPT
SCHEMBL14733493 0.85 DYRK1A (0.63) DYRK1ADYRK1B
SCHEMBL14733588 0.85 DYRK1A (0.67) DYRK1ADYRK1BEGFR
SCHEMBL14733506 0.85 DYRK1A (0.67) DYRK1ADYRK1BEGFRERBB2CYP3A4
SCHEMBL14733421 0.84 DYRK1A (0.66) DYRK1ADYRK1B
SCHEMBL14733459 0.81 DYRK1A (0.65) DYRK1ADYRK1BMKNK1
SCHEMBL14733542 0.80 DYRK1A (0.68) DYRK1ADYRK1B
SCHEMBL17060603 0.80 DYRK1A (0.75) DYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446044-B2 DYRK1 inhibitors and uses thereof DIAXONHIT (FR) 2016-09-20 US disclosed
US-9446044-B2 DYRK1 inhibitors and uses thereof DIAXONHIT (FR) 2016-09-20 US disclosed
EP-2744797-B1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2015-09-09 EP disclosed
EP-2744797-B1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2015-09-09 EP disclosed
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2014-09-18 US disclosed
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DIAXONHIT (FR) 2014-09-18 US disclosed
WO-2013026806-A1 DYRK1 INHIBITORS AND USES THEREOF EXONHIT SA (FR) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275064-A1 DYRK1 INHIBITORS AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885DYRK1B 2/4885EGFR 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.